# Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease

> **NCT04325620** · PHASE3 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 208 (actual)

## Conditions studied

- Non-erosive Gastroesphageal Reflux Disease

## Interventions

- **DRUG:** HIP1601
- **DRUG:** HGP1805

## Key facts

- **NCT ID:** NCT04325620
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-10
- **Primary completion:** 2020-08-03
- **Final completion:** 2020-08-03
- **Target enrollment:** 208 (ACTUAL)
- **Last updated:** 2022-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04325620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04325620, "Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04325620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*